AMAG Pharmaceuticals, Inc. (AMAG) financial statements (2021 and earlier)
Company profile
| Business Address |
1100 WINTER STREET WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 172 | 192 | 261 | 267 | 394 | 428 | 351 | ||
| Cash and cash equivalents | 113 | 120 | 150 | 138 | 253 | 287 | 212 | ||
| Short-term investments | 59 | 72 | 111 | 129 | 141 | 140 | 139 | ||
| Receivables | 94 | 78 | 83 | 83 | 85 | 85 | 103 | ||
| Inventory, net of allowances, customer advances and progress billings | 32 | 29 | 25 | 30 | 27 | 28 | 31 | ||
| Inventory | 32 | 29 | 25 | 30 | 27 | 28 | 31 | ||
| Disposal group, including discontinued operation | 77 | ||||||||
| Other undisclosed current assets | 19 | 43 | 25 | 41 | 19 | 13 | 12 | ||
| Total current assets: | 317 | 341 | 394 | 420 | 525 | 554 | 575 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 23 | 7 | 7 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 4 | 8 | 8 | 9 | 8 | 7 | 7 | ||
| Intangible assets, net (including goodwill) | 446 | 610 | 614 | 636 | 640 | 653 | 684 | ||
| Goodwill | 423 | 423 | 423 | 423 | 423 | 423 | 423 | ||
| Intangible assets, net (excluding goodwill) | 24 | 188 | 192 | 213 | 217 | 231 | 262 | ||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Disposal group, including discontinued operation, noncurrent assets | 559 | ||||||||
| Deferred income tax assets | 1 | 1 | 1 | ✕ | ✕ | ✕ | |||
| Other noncurrent assets | 0 | 0 | 1 | 0 | 0 | ||||
| Other undisclosed noncurrent assets | 8 | 1 | 1 | 1 | |||||
| Total noncurrent assets: | 475 | 626 | 630 | 653 | 650 | 662 | 1,253 | ||
| TOTAL ASSETS: | 791 | 967 | 1,024 | 1,073 | 1,175 | 1,216 | 1,827 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 204 | 199 | 241 | 177 | 144 | 172 | 205 | ||
| Accounts payable | 27 | 27 | 27 | 22 | 14 | 30 | 11 | ||
| Accrued liabilities | 177 | 172 | 214 | 156 | 130 | 142 | 194 | ||
| Deferred revenue | 1 | 1 | ✕ | ✕ | ✕ | ||||
| Debt | 4 | 4 | 4 | 21 | 21 | 21 | |||
| Disposal group, including discontinued operation | 53 | ||||||||
| Business combination, contingent consideration, liability | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | 2 | 0 | ||||
| Other undisclosed current liabilities | 4 | ||||||||
| Total current liabilities: | 208 | 204 | 246 | 183 | 165 | 193 | 279 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 297 | 276 | 273 | 266 | 262 | 258 | 722 | ||
| Long-term debt, excluding current maturities | 277 | 273 | 269 | 266 | 262 | 258 | 722 | ||
| Operating lease, liability | 20 | 3 | 4 | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt | 0 | 5 | 6 | 5 | 1 | 2 | 100 | ||
| Deferred revenue | 5 | 5 | ✕ | ✕ | ✕ | ||||
| Contract with customer, liability | ✕ | ✕ | ✕ | 4 | |||||
| Disposal group, including discontinued operation, liabilities | 98 | ||||||||
| Other liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||
| Business combination, contingent consideration, liability | 0 | 0 | 0 | 0 | 1 | 1 | |||
| Other undisclosed noncurrent liabilities | 4 | ||||||||
| Total noncurrent liabilities: | 297 | 282 | 278 | 275 | 263 | 260 | 822 | ||
| Total liabilities: | 505 | 486 | 525 | 458 | 429 | 454 | 1,101 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 286 | 481 | 500 | 615 | 747 | 762 | 727 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 1,298 | 1,292 | 1,288 | 1,282 | 1,293 | 1,286 | 1,282 | ||
| Accumulated other comprehensive loss | (3) | (3) | (3) | (3) | (4) | (4) | (4) | ||
| Accumulated deficit | (1,009) | (809) | (785) | (665) | (542) | (520) | (551) | ||
| Total stockholders' equity: | 286 | 481 | 500 | 615 | 747 | 762 | 727 | ||
| TOTAL LIABILITIES AND EQUITY: | 791 | 967 | 1,024 | 1,073 | 1,175 | 1,216 | 1,827 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 90 | 84 | 78 | 76 | 88 | 122 | 146 | |
| Cost of revenue | (43) | (21) | (24) | (18) | (174) | (136) | (77) | |
| Cost of goods and services sold | (43) | (21) | (24) | (18) | ||||
| Gross profit: | 46 | 63 | 54 | 57 | (86) | (14) | 69 | |
| Operating expenses | (240) | (81) | (170) | (175) | 67 | (6) | (28) | |
| Operating income (loss): | (194) | (18) | (116) | (118) | (19) | (19) | 42 | |
| Nonoperating expense | (6) | (5) | (5) | (5) | (4) | (48) | (15) | |
| Investment income, nonoperating | 1 | 1 | 1 | 2 | 2 | 2 | 1 | |
| Interest and debt expense | (7) | (6) | (6) | (6) | (36) | (16) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (206) | (30) | (127) | (129) | (23) | (103) | 11 | |
| Other undisclosed income from continuing operations before income taxes | 7 | 6 | 6 | 6 | 36 | 16 | ||
| Income (loss) from continuing operations before income taxes: | (200) | (23) | (121) | (122) | (23) | (67) | 27 | |
| Income tax expense (benefit) | 0 | (0) | 0 | 0 | 3 | 2 | (53) | |
| Loss from continuing operations: | (200) | (24) | (121) | (122) | (21) | (65) | (26) | |
| Income from discontinued operations | 1 | 6 | 6 | |||||
| Net loss: | (200) | (24) | (121) | (122) | (20) | (59) | (20) | |
| Other undisclosed net income (loss) attributable to parent | (3) | 90 | ||||||
| Net income (loss) available to common stockholders, diluted: | (200) | (24) | (121) | (122) | (22) | 31 | (20) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (200) | (24) | (121) | (122) | (20) | (59) | (20) | |
| Comprehensive loss: | (200) | (24) | (121) | (122) | (20) | (59) | (20) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | (0) | 0 | 1 | (2) | 90 | 0 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (200) | (24) | (120) | (121) | (22) | 31 | (20) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.